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Abstract Neonatal platelets are hypo-reactive to the tyrosine kinase-linked receptor agonist
collagen. Here, we have investigated whether the hypo-responsiveness is related to
altered levels of glycoprotein VI (GPVI) and integrin α2β1, or to defects in downstream
signalling events by comparison to platelet activation by C-type lectin-like receptor 2
(CLEC-2). GPVI and CLEC-2 activate a Src- and Syk-dependent signalling pathway
upstream of phospholipase C (PLC) γ2. Phosphorylation of a conserved YxxL sequence
known as a (hemi) immunotyrosine-based-activation-motif (ITAM) in both receptors is
critical for Syk activation. Platelets from human pre-term and full-term neonates
display mildly reduced expression of GPVI and CLEC-2, as well as integrin αIIbβ3,
accounted for at the transcriptional level. They are also hypo-responsive to the two
ITAM receptors, as shown by measurement of integrin αIIbβ3 activation, P-selectin
expression and Syk and PLCγ2 phosphorylation. Mouse platelets are also hypo-
responsive to GPVI and CLEC-2 from late gestation to 2 weeks of age, as determined
by measurement of integrin αIIbβ3 activation. In contrast, the response to G protein-
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Introduction
Platelets are anuclear haematopoietic cells that play an essen-
tial role inhaemostasis and itspathological counterpart throm-
bosis. Platelets alsoplay critical roles in other physiological and
pathological processes including inﬂammation,1 infection,2
vascular integrity,3 development4 and cancer metastasis.5
Currently, we have a rudimentary understanding of the role
of platelets inmanyof these functions andhow theseprocesses
vary during development and throughout adulthood.
Thrombopoiesis takes place in multiple sites during devel-
opment, beginning in the yolk sac before moving to the liver
andﬁnally to thebonemarrowand spleen.6–8 Thismeans that,
throughout development, circulating platelets are derived
frommore thanonehaematopoietic site. It ispresently unclear
to what extent this inﬂuences platelet function.
It is widely acknowledged that platelet reactivity is
reduced in neonates, but the molecular basis underlying
this is not known; the degree of hypo-reactivity and the
extent to which this varies between agonists is also uncer-
tain.9–12 This is partly due tomethodological issues related to
the low volumes of blood available for experimentation, with
many studies limited to single concentrations or small panels
of agonists.9–12 One consistent feature is a marked reduction
in responsiveness to collagen.13,14 Collagen activates Src and
Syk tyrosine kinases downstream of the glycoprotein VI
(GPVI)-Fc receptor γ-chain (FcRγ) complex, culminating in
activation of PLCγ2.15 Collagen also binds to integrin α2β1
which supports adhesion and net binding to GPVI.15 How-
ever, no difference in α2β1 expression between neonatal and
adult platelets has been reported,10,13 with the reduced
response to collagen being attributed to a reduction in
phosphoinositide hydrolysis and Ca2þmobilization suggest-
ing a defect in collagen signalling.13,16
There are also reports of impaired responses to G protein-
coupled receptor (GPCR) agonists, although this has not been
seen in all cases, and several mechanisms have been pro-
posed. The reduced response to adrenaline and thrombin has
been attributed to decreased receptor expression, and in the
case of thromboxane A2 mimetic U46619, to defective G
protein-coupled activity.10,17,18
Platelets from pre-term infants are also hypo-reactive in
comparison to their full-termcounterparts.14,19 In thewestern
world, more than 10% of babies are pre-term20 and this
population displays the highest incidence of intra-ventricular
haemorrhage (IVH). IVH affects up to 25% of infants bornwith
weights of less than 1,500 g and usually occurs in the ﬁrst
week of life.11 The increase in risk of bleeding coinciding with
the timeofmarkedplatelet hypo-reactivity raises thequestion
of whether this contributes to the increase in IVH.21,22
In this study, we have assessed the reactivity of human
platelets from pre- and full-term neonates and that of mice
platelets during late gestation and in neonates to collagen-
relatedpeptide (CRP) and to thesnakevenomtoxin rhodocytin
which activate GPVI and C-type lectin-like receptor 2 (CLEC-2),
respectively.23 Since CLEC-2 signals through a similar pathway
to GPVI, a decrease in responsiveness to CLEC-2 could reﬂect a
reduction in immunotyrosine-based-activation-motif (ITAM)
signalling, rather than a speciﬁc loss of response to GPVI.
Improving our understanding of the underlying mechanisms
of platelet hypo-reactivity in foetal and neonatal life, will help
to deﬁne the contribution of platelet hypo-reactivity in neo-
natal bleeding disorders and guide clinical decision making
and management of haemostasis and thrombosis complica-
tions especially in the case of pre-term neonates.
Materials and Methods
Materials
The platelet glycoprotein screen assay kit for analysis of
human GPIIIa (β3-integrin subunit), GPIbα and GPIa
and the platelet calibrator kit for analysis of GPVI and
CLEC-2 were from Biocytex (Marseille, France). Antibodies
for the platelet calibrator kit were as follows: GPVI-mAb
1G524; α-CLEC-2-mAb AYP124; α-CD41aAPC; and α-
CD62PE was from BD Biosciences (Madrid, Spain); and
FibrinogenAlexa Fluor 488 was from Life Technologies
(Madrid, Spain). Protease-activated receptor 1 (PAR-1) pep-
tide (TFLLR) and phorbol 12-myristate 13-acetate (PMA)
were from Sigma-Aldrich (Madrid, Spain), and Human
PAR-4 peptide (AYPGKF)was fromAlta Biosciences (Birming-
ham, UK). Integrilin (eptiﬁbatide) was from Glaxosmithkline
(Middlesex, UK). Sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) gels, polyvinylidene diﬂuor-
ide (PVDF) membranes, peroxidase conjugated secondary
antibodies and enhanced chemiluminescence (ECL) mix
were from GE Healthcare (Madrid, Spain). α-PLCγ2 (B-10),
α-Syk (4D10) and anti-Fcγ chain (sc-390222, FcεRIγ [E-12])
coupled receptor agonists was only mildly reduced and in some cases not altered in
neonatal platelets of both species. A reduction in response to GPVI and CLEC-2, but not
protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse
platelets following immune thrombocytopenia, whereas receptor expression was not
impaired. Our results demonstrate developmental differences in platelet responsive-
ness to GPVI and CLEC-2, and also following immune platelet depletion leading to
reduced Syk activation. The rapid generation of platelets during development or
following platelet depletion is achieved at the expense of signalling by ITAM-coupled
receptors.
Thrombosis and Haemostasis Vol. 118 No. 6/2018
ITAM-Receptor Signalling in Neonatal Platelets Hardy et al.1010
were from Santa Cruz (Heidelberg, Germany). α-PLCγ2-
Y1217 and α-Syk-525/526 were from Cell Signaling Technol-
ogy (Leiden, The Netherlands). α-βActin was from Sigma-
Aldrich and α-GPVI was from Abcam (Cambridge, UK). Anti-
αIIb antibody 132.1 was a gift from Z.M. Ruggeri (Scripps
Clinic, La Jolla, California, United States). For assays in mice,
the antibodies were as follows: The mouse CLEC-2 mono-
clonal antibody (mAb) 17D9 and α-IgG2bFITC were pur-
chased from Bio-Rad (Hemel Hempstead, UK). α-P-
SelectinPE was from Novus Biologicals (Abingdon, UK). α-
CD41APC and α-CD41PE were from eBioscience (Hatﬁeld,
UK) and BD Pharmigen (Oxford, UK), respectively. α-
CD41FITC, α-CD42bFITC, α-CD49bFITC, α-GPVIFITC and
α-IgGFITC were from Emfret (Eibelstadt, Germany). α-
GPIbα and immunoglobulin G (IgG) control used for immune
depletion were also from Emfret. α-CLEC-2FITC was from
AbD Serotec (Kidlington, UK). Goat α-Rat488 secondary
antibody was from Fischer Scientiﬁc (Loughborough, UK).
Other reagents were from recognized suppliers and of the
highest analytical grade commercially available.
Human Blood Collection
Cord blood (CB) samples were collected from healthy pre-term
(26–34 gestational weeks) and full-term neonates ( 37 gesta-
tional weeks), admitted to the maternal-fetal unit of the Uni-
versity Hospital Virgen de la Arrixaca, Murcia, Spain. All
neonates were born from uncomplicated pregnancies and
had a normal platelet count (> 150,000 platelets/μL). Neonates
were excluded from the study if mothers had a history of
diabetes, hypertension, pre-eclampsia, active infection, drug or
alcohol abuse, had taken aspirin during the 10 days prior to the
delivery or therewas a family history of abnormal haemostasis
or any congenital disorder. Peripheral blood (PB) samples were
collected fromthe antecubital veins of healthyadult volunteers
who had not taken anymedications during the 10 days prior to
the study. All samples (CB and PB) were drawn in to 3.2%
buffered sodium citrate tubes (Vacutainer System; Diagnostica
Stago Becton Dickinson, Plymouth, UK). The study on humans
was approved by the Ethics Committee of the Arrixaca
University Hospital and followed the Helsinki Declaration. All
adult volunteers and the parents of neonates providedwritten
informed consent.
Murine Blood Collection
Mouse embryos were dissected from pregnant females after
maternal cervical dislocation, before being decapitated and
allowed to bleed into 10 units/mL of heparin in phosphate-
buffered saline (PBS). Neonatal mice were culled via intra-
peritoneal injection of Euthatal (50–100 µL) before being
decapitated and allowed to bleed into 10 units/mL of heparin.
Where stated, adultmicewere culled as for neonates to enable
comparison of results of platelets prepared in the same way.
Otherwise, adult mice were anaesthetised with isoﬂurane
before CO2 narcosis, descending vena cava isolation and sub-
sequent venepuncture collection.
For repeat blood collection from immune-induced throm-
bocytopenic mice, the animals were restrained and blood
was withdrawn from the tail vein via needle-prick into
10 units/mL heparin; terminal bleeds were performed under
isoﬂurane/CO2 as described above. All animal work was
performed with U.K. Home Ofﬁce approval under license
PPL70/8286.
Receptors Levels and Platelet Activation in Human
Platelets
Platelet receptor expression in adult, pre-term and full-term
blood samples was assessed by ﬂow cytometry using a BD
Accuri C6 ﬂow cytometer device (Ann Arbor, Michigan,
United States). The GP Screen and Platelet Calibrator kits
(Biocytex), with the appropriate antibodies as stated above,
were used following the manufacturer’s instructions.
Adult blood and CB samples from both pre-term and full-
term neonates were also assessed for agonist-induced sur-
face P-selectin exposure and ﬂuorescent ﬁbrinogen binding
to αIIbβ3 by ﬂow cytometry using Accuri C6. Brieﬂy, diluted
blood was incubated under static conditions (30 minutes at
room temperature) with PBS, as control for non-stimulated
platelets, PAR-1 peptide (25 µM), PAR-4 peptide (250 µM),
adenosine diphosphate (ADP) (25 µM), PMA (100 nM), CRP
(5 µg/mL) and rhodocytin (100 nM) in the presence of α-
CD41aAPC, as platelet marker antibody, α-CD62PE and
ﬁbrinogenAlexa Fluor 488. Reactions were terminated by
4% paraformaldehyde (PFA) (v/v) and subsequent 10-fold
dilutionwith PBS. For each sample, run up to 10,000 platelets
were identiﬁed and analysed by gating events on both
CD41aAPC positivity and forward scatter-side scatter (FSC-
SSC). Results were expressed as percentage of positively
stained cell for P-selectin or ﬁbrinogen, as compared with
non-stimulated cells.
Assessment of GPVI and CLEC-2 Signalling Pathway in
Human Platelets by Immunoblotting
Human adult and full-term neonates’ washed platelets in
modiﬁed Tyrode’s buffer were obtained as previously
described.25 For protein phosphorylation studies, washed
platelets (6  108/mL) were stimulated under stirring condi-
tions for 180 seconds with CRP (1–10 µg/mL) or rhodocytin
(30–100 nM), using an aggregometer set at 37°C (Aggrecorder
II Menarini Diagnostics, Florence, Italy). Eptiﬁbatide (1 µM)
was included to prevent platelet aggregation and stimulation
was stopped by addition of SDS reducing sample buffer.
Proteins in whole cell lysates were separated by SDS-PAGE
and transferred to PVDF membranes by means of semi-dry
transfer units.Blotswerestepwise incubatedwithappropriate
primary antibodies and as peroxidase-conjugated secondary
antibodies (see the “Materials” section), and proteins were
detected by chemiluminescence.
Gene Expression Analysis of GP6, CLEC1B, SYK and
PLCG2 in Human Platelets
Total ribonucleic acid (RNA) was isolated from ultrapure plate-
lets as we have recently reported in detail.26 Retrotranscription
reactionwasperformedusing35.2 ngof total RNA, according to
the manufacturer’s instructions (SuperScript III First Strand,
Thermo Fisher Scientiﬁc). Gene expressionwas quantiﬁed on a
LC480 real-time polymerase chain reaction (PCR) system
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(Roche Pharma, Basel, Switzerland) using Taqman Premix Ex
Taq (Takara Bio Inc.) and a commercial probe for GP6 (Hs_0
0212574), FCER1G (Hs_Hs00175408), CLEC1B (Hs_00212925),
SYK (Hs_00895377),PLCG2 (Hs01101857_m1)andACTB (Hs_99
999903).
Murine Platelet Receptor Expression and Platelet
Activation
To evaluatemurineplatelet receptor expression, dilutedwhole
blood (10–20  109 platelets/L) was stained (30 minutes at
room temperature) with both α-CD41APC and a ﬂuorescein
isothiocyanate (FITC)-labelled antibody (see above) speciﬁc to
the target receptor: GPIbα, αIIbβ3, α2β1, GPVI and CLEC-2.
Reactions were terminated with 4% PFA solution and 10-fold
PBSdilutionasabove, andplatelets acquiredandanalysedwith
the Accuri C6 software. Results were expressed as mean
ﬂuorescence of positive cells. Agonist-induced platelet activa-
tion inmice at known pre- and post-natal ages was evaluated,
as in the human studies above, by ﬂow cytometric analysis of
ﬁbrinogen-binding and P-selectin exposure in PBS-diluted
murineblood (10–20  109platelets/L).Agonistsused in these
assays include PBS, as control for non-stimulated platelets,
PAR-4 peptide (50, 100 and 250 µM), CRP (1, 5 and 10 µg/mL)
and rhodocytin (10, 30 and100nM). Resultswere expressedas
percentage ofmurine platelets positively stained for P-selectin
or ﬁbrinogen, as compared with non-stimulated cells.
Murine Recovery from Immune-Mediated
Thrombocytopenia
Immune thrombocytopenia was induced in adult mice by
injection of 1.5 µg/g α-GPIbα, which caused a sharp and
rapid decline in platelet count.27 Control mice were injected
with IgG control. Blood samples were collected before injec-
tion and daily post-injection for analysis of platelet receptor
expression and dose–response assays as described above.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism
V7.00 (California,UnitedStates). Differences betweenneonates
and adults in platelet receptor levels, gene expression levels or
platelet functional responses were assessed by t-test orMann–
WhitneyUtestasappropriated. Formurine receptorstudies,an
ordinaryone-wayanalysis of variance (ANOVA)wasperformed
withaposthocDunnet’smultiplecomparisonstest. Formurine
neonatal and post-thrombocytopenia functional assays, a two-
way ANOVAwas performedwith a Dunnet’s multiple compar-
isons post hoc test. For murine post-thrombocytopenia recep-
tor assays, a two-way ANOVA was performed with a Sidak’s
multiple comparisons post hoc test. Signiﬁcance was assumed
with a p-value of  0.05 () or  0.005 ().
Results
Platelets from Pre-Term and Full-Term Neonates
Display Reduced Expression and Function of GPVI and
CLEC-2
We explored themean platelet volume and expression levels
of human platelet receptors in pre-term neonates (median
gestational age of 32.3 [range, 29.8–34.4] weeks), full-term
neonates and adults. The mean platelet volume was similar
in all three groups (►Supplementary Fig. S1A, available
in the online version). In contrast, there was a signiﬁcant
(30–35%) reduction in the levels of GPVI and CLEC-2 in pre-
term and full-term neonates versus adults as shown by ﬂow
cytometry (►Fig. 1A) and by immunoblotting (►Fig. 1B). In
agreement with the above ﬁndings, quantitative reverse
transcription PCR (qRT-PCR) experiments showed that neo-
natal platelets displayed a signiﬁcant reduction in GP6 (60%)
and amild decrease in CLEC1B (30%)messenger RNA (mRNA)
levels, compared with adult platelets (►Supplementary
Fig. S2A, B, available in the online version). In line with the
decrease in GPVI, the expression of Fcγ chain, which asso-
ciated with GPVI to form a functional collagen immunor-
eceptor,28,29 was also reduced at protein and mRNA level in
neonatal platelets (►Supplementary Fig. S3A–C, available in
the online version). In addition, and in concordance with
previous studies,10 pre-term and full-term neonates dis-
played a mild reduction in expression of integrin αIIbβ3,
but no signiﬁcant change in the levels of integrin α2β1 and
GPIbα (►Fig. 1A).
Developmental changes in human platelet reactivity were
assessed in ﬂow cytometric experiments by monitoring
ﬁbrinogen-binding and P-selectin expression following pla-
telet stimulation. Compared with adults, platelets from pre-
term and full-term neonates exhibited amarked reduction in
ﬁbrinogen binding in response to CRP, rhodocytin and PAR-1
(over 50%), along with amoderate decrease for ADP and PMA
(25%) and no change in response to PAR-4 (►Fig. 1C).
Agonist-induced platelet expression of P-selectin, a marker
of α-granule release, was also signiﬁcantly decreased in pre-
term versus adult platelets for CRP, rhodocytin and PAR-1. In
full-term neonates, P-selectin exposure was markedly
reduced in response to CRP and rhodocytin, with only a
mild decrease in PAR-1 (►Fig. 1D).
These results demonstrate a hypo-sensitivity to GPVI and
CLEC-2 agonists, which is in part explained by a decrease in
receptor expression.
Expression and Tyrosine Phosphorylation of Syk and
PLCγ2 is Reduced in Neonatal Platelets
To investigate whether ITAM receptor signalling varies during
development and contributes to the defect in platelet activa-
tion by GPVI and CLEC-2, human platelets from full-term
neonates and adultswere compared for Syk and PLCγ2 expres-
sion, and for tyrosine phosphorylation of these key signalling
proteins after stimulationwith CRPand rhodocytin. Therewas
a reduction in the total level of Syk and PLCγ2 proteins in
resting neonatal plateletswhen comparedwith adult platelets
(Syk: 0.53  0.14 vs. 0.73  0.19 arbitrary units; PLCγ2:
0.15  0.1 vs. 0.27  0.06 arbitrary units) as measured by
western blotting (►Fig. 2). The gene expression level of SYK
was also lower in platelets from full-term neonates versus
adult platelets (►Supplementary Fig. S2C, available in the
online version). The level of PLCγ2 mRNA was too low for
quantitation. Stimulation with either CRP or rhodocytin for
5 minutes induced dose-dependent tyrosine phosphorylation
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ofSykandPLCγ2,asassessedwithphospho-speciﬁcantibodies
to the activation site in Syk (residues 525/526)30 and to an
established marker of PLCγ2 activation (Tyrosine 1217).31 As
illustrated in ►Fig. 2, phosphorylation of Syk and PLCγ2 was
markedly reduced in neonatal platelets at all concentrations of
CRP (►Fig. 2A, B) and rhodocytin (►Fig. 2C, D). This reduced
phosphorylation of Syk and PLCγ2 in neonatal platelets is still
appreciable after normalization for the reduced level of
expression of Syk and PLCγ2 (►Fig. 2E, F), thus supporting
the impairment in the signal transduction pathway common
to GPVI and CLEC-2 in full-term neonates.
Gestational and Neonatal Mice Platelets Display a
Hypo-Reactivity to GPVI and CLEC-2
To further assess the inﬂuence of the gestational age on the
change in platelet reactivity, we extended our research to
mouse platelets (E17.5 to P14.5 and adult). As with human
studies, we ﬁrst measured the levels of GPVI, CLEC-2 and
othermajor glycoproteins by ﬂowcytometry. Aswith human
platelets, a mild reduction in the levels of GPVI and CLEC-2
was observed in gestational and neonatal mice platelets
relative to adults (►Fig. 3), which cannot be explained by a
change in mean platelet volume (►Supplementary Fig. S1B,
available in the online version).
We performed functional studies on the murine plate-
lets in response to CRP, rhodocytin and PAR-4 peptide.
Foetal (E17.5) and early neonatal (P1.5–P7.5) mice plate-
lets displayed a signiﬁcant impairment in ﬁbrinogen bind-
ing in response to all concentrations of CRP (►Fig. 4A) and
to low and moderate concentrations of rhodocytin
(►Fig. 4B). By 2 weeks of age (P10.5–P14.5), mice platelets
stimulated with high concentrations of rhodocytin
recovered their ﬁbrinogen-binding capacity (►Fig. 4B).
In contrast, we observed only a mild reduction in ﬁbrino-
gen binding of murine platelets aged E17.5 to P14.5 in
response to PAR-4 peptide (►Fig. 4C). A more severe
decrease in response was observed in mice platelets for
agonist-induced expression of P-selectin. Thus, as com-
pared with adults, the surface expression of the α-granule
protein was signiﬁcantly reduced for all three stimuli in
foetal and neonatal mice platelets, with recovery increas-
ing with age (►Fig. 4D–F).
These results demonstrate that as with human platelets,
mouse platelets show impairment in response to GPVI and
CLEC-2 in foetal, neonatal and early post-natal life. In the case
for PAR-4, they also show a marked reduction for the
expression of P-selectin, and a mild decrease in activation
of αIIbβ3 in late gestational and neonatal platelets.
Fig. 1 Flow cytometric assessment of receptor expression and function in platelets from premature, full-term neonates and adults. Platelet receptor
expressionwasmeasuredby (A)ﬂowcytometryusingBiocytex kits inhumanpre-term(whitebars;n ¼ 5) and full-term(redbars;n ¼ 8–11)neonates and in
adults (blue bars; n ¼ 8–11), and by (B) western blotting, as described in the “Material and Methods” section. Western blots images are representative of
assays inplatelet lysates fromdifferent full-termneonates (n ¼ 6) andadults (n ¼ 6). Inactivationexperiments,platelets fromneonates (whiteand redbars;
n ¼ 5 and n ¼ 6, respectively) and adults (blue; n ¼ 6) were activated by collagen-related peptide (CRP) (5 μg/mL), rhodocytin (100 nM), adenosine
diphosphate (ADP) (25µM),Protease-activated receptor (PAR)-1 (25µM)andPAR-4 (250µM)peptides, andphorbol12-myristate13-acetate (PMA) (100nM).
The binding of ﬂuorescently labelled ﬁbrinogen (C) and the P-selectin exposure (D), was monitored for 30minutes at room temperature (RT), post-agonist
stimulation. Values are mean plus standard deviation.  and  denote p  0.05 and p  0.005, respectively, versus adults.
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Platelets are Hypo-Responsive to GPVI and CLEC-2
following Immune-Induced Thrombocytopenia
We hypothesized that the hypo-responsiveness to GPVI and
CLEC-2 may be related to the need to generate sufﬁcient
numbers of platelets to keep pace with the growth of
embryos and neonates. To model this high-pressure platelet
production environment in adult mice, we established an
immune-induced thrombocytopenia mice model in which
we assessed the platelet receptor levels and activation by
GPVI, CLEC-2 and PAR-4. We observed that the new platelets
generated following immune depletion have increased size
(►Supplementary Fig. S1C, available in the online version). In
concordance with this ﬁnding, the level of αIIbβ3 and α2β1
integrins increased slightly following immune depletion
(►Fig. 5). In contrast, we observed no signiﬁcant changes
in the expression of the ITAM receptors, GPVI and CLEC-2,
following immune depletion (►Fig. 5).
The increase in ﬁbrinogen-binding and P-selectin expres-
sion in response to CRP was markedly reduced in the ﬁrst few
days following immune thrombocytopenia (►Fig. 6A, D). A
similar but less severe pattern was observed in response to
low-to-moderate concentrations of rhodocytin (►Fig. 6B, E).
By contrast, therewasno decline inplatelet activation induced
by PAR-4 following immune thrombocytopenia (►Fig. 6C, F).
Discussion
Several studies have shown that neonatal platelets are hypo-
responsive to various agonists such as ADP, epinephrine,
thromboxane analogues, thrombin and collagen. This is char-
acterized by decreased aggregation, secretion and expression
of platelet activation upon stimulation. There is considerable
variation among these studies on the degree of reduction in
platelet reactivity, which most likely relates to differences in
Fig. 2 Expression and phosphorylation of Syk and PLCγ2 in platelets from adult and full-term neonates in response to collagen-related peptide
(CRP) and rhodocytin. Human washed platelets were diluted to 600  109 platelets/L and stimulated with different dose of CRP (A, B; E, F) and
rhodocytin (C, D) for 5 minutes under stirring conditions. Reactions were stopped by adding one volume of 5 reducing sample buffer. In panels
E and F, identical amounts of total Syk (E) and PLCγ2 (F) were loaded in the gel. Samples were developed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and analysed using phospho-speciﬁc antibodies. The images shown are representative of 4 (A–D)
and 3 (E, F) experiments with independent platelet samples.
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procedures for blood sampling, platelet function testing and
limited sample volume.10–12,19,32 Developmentally regulated
expression of platelet receptors and receptor-coupled signal
transduction can underlie the different reactivity of neonatal
and adult platelets.11,12,32 This study focused on the expres-
sion and function of the ITAM receptors GPVI and CLEC-2
during development in human and murine species, and in a
murine model of haematopoietic stress. Hypo-responsiveness
of neonatal platelets to collagen has been consistently seen in
previous studies, and is more dramatic than that to GPCR
agonists.9–14
In agreement with previous reports, we observed develop-
mental regulation of the expression ofmajor adhesive platelet
receptors in human (αIIbβ3;►Fig. 1)10,12,19 and mice (GPIbα,
andαIIbβ3 andα2β1 integrins;►Fig. 3).33Wespeculate that a
moderate but signiﬁcantly reduced level of integrin αIIbβ3 in
platelets from pre-term and full-term neonates contributes to
the mild impairment in αIIbβ3 activation (i.e. ﬁbrinogen
binding) by all agonists. In mice, however, αIIbβ3 levels in
gestational and early post-natal life are similar to that in adults
(►Fig. 3), while there is a marked impairment in ﬁbrinogen
binding in response to CRP, rhodocytin and, to a lesser extent,
PAR-4. Thus, this defect may bemainly contributed by impair-
ment in agonist-induced conformational changes and activa-
tion of the integrin, which was not evaluated in this study.
Themajor novelﬁndingofourwork is thatduring foetal and
neonatal life platelet signalling through GPVI and CLEC-2 is
impaired inmiceandhumanplatelets.While this investigation
was underway, a study has also observed a reduced platelet
response toCRPand rhodocytin inneonatal humanplatelets.34
In addition to extending these ﬁndings to an earlier stage in
humandevelopment (pre-term infants) and todevelopment in
mice,we also show, for theﬁrst time, that twomechanisms act
synergistically to give rise to the impaired response to the two
ITAM receptor agonists. Theﬁrst one is a reduction in the level
of GPVI, its associated protein Fcγ chain28,29 and CLEC-2 in
neonatal human platelets. This reduction is not accounted by
signiﬁcant changes in platelet volume (►Supplementary
Fig. S1, available in the online version), but is associated to
changes at the transcriptional level, as indicated by reduced
GP6, FCER1G and CLEC1B mRNA levels compared with adult
platelets (►Supplementary Figs. S2 and S3, available in the
online version). Consistently, the level of these ITAM receptors
is also reduced in gestational and neonatal murine platelets
compared with adult platelets. In this study, we found no
signiﬁcant changes in platelet volume during mice develop-
ment (►Supplementary Fig. S1, available in the online
version), contrarily to previous study.7 This discrepancy is
most likely due toanalytical differences inbloodcollectionand
the device used to assess platelet volume.
The second mechanism contributing to the hypo-respon-
siveness of neonatal platelets to GPVI and CLEC-2 agonists is a
regulation in development of the expression of key proteins in
ITAM receptor signalling, such as Syk and PLCγ2,most likely at
the transcriptional level asneonatalplateletsdisplay lowerSYK
mRNA levels. The mechanisms underlying transcriptional
differences in genes of the ITAM receptor pathways remain
unknown, and may include potential changes in the activity
of factors involved in the regulation of GP6, FCER1G, CLEC1B
and SYK.
Taken together, these two mechanisms contribute, in
a degree that cannot be delineated from our study, to a
signiﬁcant impairment of signalling downstream of GPVI and
CLEC-2, as reﬂected by a reduced Syk and PLCγ2 phosphoryla-
tion (this study), and the previously reported decrease in Ca2þ
mobilization in neonatal platelets in response to collagen.16
Fig. 3 Receptor expression in mouse platelets during development. Platelet surface receptor expression proﬁles in mice platelets were assessed
by ﬂow cytometry with ﬂuorescently labelled antibodies, as reported in the “Materials and Methods” section. Results are expressed as mean plus
standard deviation of the median ﬂuorescence of platelet populations in different mice (gestational and neonatal platelet, n ¼ 12–26; adults
platelets n ¼ 6); p  0.05; p  0.005
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Moreover, using a mouse model, we show that the
responses to GPVI and CLEC-2 are also sharply reduced in
adult mice within the ﬁrst 3 days of recovery from immune
thrombocytopenia, where a high thrombopoietic pressure
would exist (►Fig. 6). Thisﬁnding is in agreementwith avery
recent study showing that GPVI-ITAM signalling is partially
inactive in newly formed platelets generated in response to
acute thrombocytopenia.35 Thus, it could be speculated that
the rapid generation of platelets at the time of need (i.e. in
development and recovery from a marked decrease in plate-
let count) may be due to induction of neonatal thrombopoi-
esis, thus resembling generation of red cells in response to
acute anaemia which occurs through neonatal rather than
adult erythropoiesis.36–38However, our current data suggest
that the pattern of murine platelet reactivity following
immune depletion in mice is complex and likely inﬂuenced
by multiple factors. For instance, we observed an increased
P-selectin exposure of days 7 to 9 platelets after depletion, in
response to PAR-4 and rhodocytin. This is unlikely due to an
increased platelet size, which is almost negligible at days 7 to
9 as compared with days 2 to 5 after depletion, and may be
related to the rebound in platelet reactivity to these agonists.
Fig. 4 Agonist-induced activation of mouse platelets during development. Activation of mouse platelets during development was monitored by ﬂow
cytometry for (A–C) ﬂuorescently labelled ﬁbrinogen binding and (D–F) expression of P-selectin expression in response to (A, D) collagen-related peptide
(CRP) (2, 5, 10 µg/mL); (B, E) rhodocytin (10, 30, 100 nM) and (C, F) protease-activated receptor (PAR)-4 peptide (50, 100, 250 µM). Values are mean plus
standard error of the percentage of positive labelled platelets achieved in 3 to 9 different samples per group.  and  denote p  0.05 and p  0.005,
respectively, in comparison to values in adults platelets.
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In addition, we found a puzzling increase in ﬁbrinogen
binding of days 4 to 5 platelets in response to 10 nM
rhodocytin. In their recent study, Gupta et al35 found that
newly formed young platelets have increased reactivity to
thrombin when immune depletion is achieved by an anti-
GPIbα antibody, but not if this is induced by anti-αIIbβ3
antibody (day 5). They also found an unaltered response to
rhodocytin (1 μg/mL) at day 5 following immune thrombo-
cytopenia. Further studies are required to fully clarify the
responsiveness of newly formed young platelets released
after immune thrombocytopenia.
In contrast to the study of Baker-Groberg et al showing
higher platelet-surface P-selectin expression in resting neo-
natal platelets,34we found that this expressionwas similar to
that in resting adult platelets. The fact that we used adult
venous blood and CB, whereas the previous study assayed
capillary blood,34 may account for the discrepancy. As in
humans, in resting conditions, the platelet surface P-selectin
levels were similar in murine neonatal and adult platelets.
Moreover, the level of P-selectin expression was unaffected
following immune thrombocytopenia. Notably, while in
humans total P-selectin content is similar between adult
and neonatal platelets,39 inmice it has been suggested that P-
selectin expression is developmentally regulated.40 Thus, the
marked reduction in P-selectin secretion induced by CRP and
rhodocytin in gestational and early neonatal mice platelets
that we have observed may bemediated by a combination of
reduced activation of their ITAM receptors and by develop-
mental up-regulation of the α-granule protein. In contrast,
the impaired P-selectin response to PAR-4 may be due solely
to up-regulation in development, as PAR-4-induced activa-
tion of ﬁbrinogen binding is similar in gestational, neonatal
and adult mice.
The functional signiﬁcance of this decrease in ITAM
receptor expression and signalling in platelet activation
during ontogeny is currently unclear. The foetus has little
threat of trauma during development other than the birth
process, and GPVI has a minor role in haemostasis.41 How-
ever, platelets are exposed to collagen during vasculogenesis
and angiogenesis and a reduced responsiveness to GPVI may
help to avoid unwanted thrombosis. In this context, it has
recently been reported that infusion of adult platelets into
mice at E14.5 leads to the rapid formation of occlusive
thrombi,42 and that transfusion of human adult platelets
into neonatal blood leads to a hyper-coagulable proﬁle.43
To unravel the physiological relevance of reduced CLEC-2
levels during theﬁrst stages of the development,where it plays
a key role in blood–lymphatic separation, further researchwill
be required. Podoplanin expression changes during onto-
geny44: in the ﬁrst stages, podoplanin is highly and widely
expressed, butover time itsexpressionbecomes restricted.45,46
Importantly, podoplanin is strongly expressed in the villous
stroma of the placenta,47 and during angiogenesis of the foetal
vessels, platelets could be exposed to the high amount of
placenta podoplanin. Thus, reduction of platelet levels of
CLEC-2 could be a compensatorymechanism to avoid excessive
platelet activation during development and to safeguard neo-
natal haemostasis.
Our current results are of potential clinical signiﬁcance,
especially as premature human babies have an increased risk
of IVH.11 The pathogenesis of IVH in pre-term infants is
complex and multifactorial, and the contribution of platelet
Fig. 5 Receptor levels in mice platelets before and after immune depletion. Surface receptor expression proﬁles in mice were assessed following platelet
immune depletion using ﬂuorescently labelled antibodies as described in the Supplementary Methods. Data are shown as mean plus standard deviation of
themedian ﬂuorescence of theplatelet populationachieved in12 to24different samples in eachgroup.  denotesp  0.005 versus values inmice treated
with a control immunoglobulin G (IgG) antibody (sham).
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hypo-reactivity is still unclear.48 However, the poorly devel-
oped germinalmatrix vessels in premature infants have been
established as a contributing factor in the aetiology of
IVH.32,49 Recent studies in murine embryos have demon-
strated that deﬁciency of CLEC-2 or podoplanin, its endo-
genous ligand, is associated with impaired angiogenesis and
severe brain haemorrhaging.4 During development, CLEC-2
induces platelet activation and subsequent formation of
platelet aggregates through integrin αIIbβ3, to maintain
the integrity of the nascence blood vessels in the brain.
Thus, the reduced CLEC-2 and integrin αIIbβ3 levels in
neonatal platelets that we report may contribute to the
Fig. 6 Measurement of murine platelet function following immune depletion. Mice were injected with α-GPIbα antibody to induce immune
thrombocytopenia. Blood samples were collected before platelet depletion and thereafter for up to 9 days. Platelet reactivity was measured via
(A–C) ﬂuorescent ﬁbrinogen binding and (D–F) P-selectin exposure in response to increasing doses of (A,D) collagen-related peptide (CRP), (B, E)
rhodocytin and (C, F) protease-activated receptor (PAR)-4 peptide. Data are shown as mean plus standard error of the percentage of positive
platelets achieved in 6 to 9 different samples in each group.  denotes p  0.005 versus values found in mice before injection of the α-GPIbα
antibody.
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increase risk of IVH. Moreover, apart from considering body
weight and surface on the newborns, new insights into the
mechanisms of hypo-reactivity in neonatal platelets could
aid the adjustment of anti-platelet therapy in neonates for
the prevention of arterial thrombosis in conditions such as
congenital heart disease, assist devices, prosthetic valves or
systemic-to-pulmonary shunt implants.50
There are several limitations of this study. The number of
neonatal samples is relatively low due to limited availability
and logistical difﬁculties. The use of CB as a source of
neonatal platelets might not be ideal, but it is not otherwise
possible to collect the volumes that were needed for all
assays. Importantly, however, it has been reported that
neonatal platelets from the cord and PB are similarly hypo-
reactive.19 In mice, the small sample volumes have limited
the number of functional studies that could be performed.
In conclusion, in this studyweshowthat plateletexpression
and signalling of GPVI and CLEC-2 are reduced in neonates of
mice and humans. This hypo-reactivity of ITAM receptorsmay
prevent unwanted platelet activation during vascular devel-
opment, but an excessive ITAM signalling impairment could
contribute to the increase in risk of IVH in neonates.
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